A Risk-Scoring Model for Severe Checkpoint Inhibitor-Related Pneumonitis: A Case –Control Study
ConclusionsThe simple risk-scoring model may predict severe CIP in lung cancer patients receiving ICIs. For patients with high scores, clinicians should use ICIs with caution or strengthen the monitoring of these patients.
Source: Clinical Drug Investigation - Category: Drugs & Pharmacology Source Type: research
More News: Cancer | Cancer & Oncology | Carcinoma | Chronic Obstructive Pulmonary | Drugs & Pharmacology | Emphysema | Immunotherapy | Interstitial Lung Disease | Lung Cancer | Skin Cancer | Smokers | Squamous Cell Carcinoma | Study